Semin Arthritis Rheu: Comorbidities of Rheumatic Polymyalgia

The study aims to determine thediagnosisof comorbidities in patients with rheumatoid polymyalgia (PMR), including adverse reactions associated with glucocorticoids (GC)extracted anonymous electronic medical records of patients over the age of 40 between 1990 and 2016 from the clinical practice study data chainPMR patients were matched with 3-5 controls based on age, gender and general medical registrationThe prevalence, cumulative probability and likelihood of a range of comorbidities were estimatedAfter adjusting the various covariates, the conditional logistic regression and Cox proportional risk regression are used to calculate the ratio (ORs) and the hazard ratio (HRs) respectivelymatched 31,984 PMR patients with 149,436 controlsPMR is associated withvasculardisease (corrected HR 1.23 (95% confidence interval (CI) 1.19, 1.28)) and respiratory system (HR 1.25,1.18, 1.32), kidneys (HR 1.34,1.30, 1.39)) and autoimmunedisease (HR 4.68,4.35,53) In contrast, prior to PMR diagnosis, the risk of cancer (adjusted OR (OR) 0.89 (0.86, 0.93)) and neurological disease (OR 0.36 (0.33, 0.40)) was significantly reducedPatients with PMR have an increased risk of developing comorbidities associated with the use of glucocorticoids (GC)the combined burden of PMR patients is high before and after diagnosisAlthough further work is needed to fully understand these associations, clinicians should be aware of the high prevalence of comorbidities in this group of patients and the possible effects of glucocorticoid therapy on comorbidities